Johnson & Johnson will pay 36 states and the District of Columbia $181 million as a settlement for allegations that the company inappropriately marketed its antipsychotic drug Risperdal, the Philadelphia Inquirer reports.
Federal and state investigators have been examining the company’s Risperdal marketing practices for almost a decade, according to the Inquirer. The $181 million agreement is separate from a continuing federal investigation that could lead to criminal charges against Johnson ...
continue reading...
According to a story in the New York Times, a renewed U.S. Justice Department emphasis on prosecuting corporate fraud is expected to bring in as much as $8 billion this year from pharmaceutical companies, military contractors, banks and other corporations charged with defrauding the government, which amounts to a record sum.
According to a Bloomberg report, Bayer has said that settlements of U.S. lawsuits over its Yasmin line of birth control pills have reached more than $402 million.
According to a Consumer Reports blog entry, the recent historic $3 billion settlement against pharmaceutical giant GlaxoSmithKline carries some important lessons for consumers.
Christine Scott, a woman awarded $5.5 million for injuries from a transvaginal mesh implant, said she hopes the development will help “get the word out to women,” according to a report on KGET out of California.
